Related Experiment Videos
[Long-term lithium prophylaxis in the bipolar affective disorder]
Aleksandra Suwalska1, Maria Chłopocka-Woźniak, Janusz Rybakowski
1Klinika Psychiatrii Dorosłych AM w Poznaniu.
Psychiatria Polska
|March 22, 2003
Summary
Lithium is effective for bipolar disorder, but long-term non-responders had longer illness duration before treatment. Early depressive episodes during lithium prophylaxis may predict poor treatment response.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Neuroscience
Context:
- Bipolar affective disorder (BAD) is a chronic mental health condition requiring long-term management.
- Lithium is a first-line mood stabilizer for BAD, but individual responses vary significantly.
- Understanding predictors of lithium response is crucial for optimizing patient care.
Purpose:
- To evaluate the long-term efficacy of lithium prophylaxis in bipolar affective disorder.
- To identify clinical and demographic differences between lithium responders and non-responders.
- To explore potential predictors of lithium treatment outcomes.
Summary:
- This study analyzed 103 patients with BAD treated with lithium for over 10 years.
- Excellent responders (no episodes) and partial responders (≥50% episode reduction) were identified.
- Non-responders had longer illness duration before lithium and a higher episode index prior to treatment.
- A trend towards higher lithium plasma levels in excellent responders was noted.
- Depressive episodes within the first year of lithium prophylaxis were more common in non-responders.
Impact:
- Findings suggest that longer pre-treatment illness duration and early depressive episodes during prophylaxis may indicate poor lithium response in BAD.
- Identifying non-responders early can guide clinicians in adjusting treatment strategies.
- This research contributes to personalized medicine approaches in bipolar disorder management.